RFA FOR KIDNEY CANCER
PERCUTANEOUS TREATMENT FOR SMALL RENAL MASSES
For patients with small renal cell carcinoma who have limited kidney function, a solitary kidney, or who wish to avoid surgery โ percutaneous RFA offers guideline-supported, minimally invasive treatment that destroys the tumour while preserving as much renal function as possible.
analyticsAt a Glance
- check_circleAUA and EAU guidelines: ablation is an acceptable alternative to surgery for T1a (<4 cm) RCC
- check_circleComplete ablation 90โ97% for <3 cm tumours; 80โ90% for 3โ4 cm
- check_circle5-year cancer-specific survival >95% for T1a RCC โ equivalent to partial nephrectomy
- check_circleNephron-sparing: no kidney tissue removed โ critical in CKD, solitary kidney, bilateral tumours
Why Renal Function Preservation Makes Ablation Uniquely Valuable
Kidney ablation occupies a special niche in interventional oncology โ more than any other tumour type, the rationale for ablation over surgery in kidney cancer is driven not just by lower surgical risk but by the profound importance of preserving renal function.
โEvery nephron removed in a kidney cancer operation is gone forever. In a patient who already has reduced kidney function โ or who is destined to lose function as they age โ losing additional nephrons by removing kidney tissue accelerates the journey toward dialysis. RFA destroys only the tumour. The kidney parenchyma around it heals and functions normally.โ
The Renal Function Stakes
Chronic kidney disease (CKD) affects a large proportion of patients with kidney cancer โ many have underlying hypertension or diabetes that already reduces GFR. Radical nephrectomy typically reduces GFR by 50%. Partial nephrectomy reduces GFR less, but still removes the tumour plus a margin of normal kidney. RFA removes only the tumour, leaving the surrounding nephrons intact. For patients with baseline CKD, this difference can mean the difference between preserved kidney function and dialysis dependency.
Clinical Scenarios Where Preservation Is Critical
Solitary kidney (contralateral kidney removed or absent). Bilateral renal tumours (both kidneys affected simultaneously or sequentially). Baseline CKD (eGFR <60 mL/min). Von Hippel-Lindau syndrome or other hereditary renal cancer syndromes producing multiple tumours over a lifetime. Elderly patients where surgical recovery risk is elevated and future kidney function decline is expected from ageing alone.
Eligibility Criteria for Renal RFA
AUA and EAU guideline parameters for renal mass ablation โ and where the boundaries of appropriateness lie.
| Factor | Suitable for RFA | Consider Surgery or Other Approach |
|---|---|---|
| Tumour Size | T1a: โค4 cm โ ideal. Best outcomes <3 cm | T1b: 4โ7 cm โ ablation possible but lower efficacy; surgery preferred for fit patients |
| Histology Known | Biopsy-confirmed RCC or high-suspicion on imaging | Indeterminate on biopsy โ discuss with MDT; some may be benign |
| Tumour Location | Exophytic (protruding from kidney surface) โ ideal; peripheral cortical | Central hilar (adjacent to renal pelvis, ureter, or major vessels) โ high risk of urothelial or vascular injury; specialist centre required |
| Renal Function Concern | Solitary kidney; bilateral tumours; baseline CKD; hereditary RCC syndrome | Normal contralateral kidney with young fit patient โ partial nephrectomy preferred for best local control |
| Patient Fitness | High surgical risk; comorbidities elevating anaesthetic or surgical mortality | Young, fit patient with normal contralateral kidney โ partial nephrectomy provides better pathological staging |
| Coagulation | INR <1.5; platelets >50,000; hold anticoagulants per protocol | Severe uncorrectable coagulopathy โ assess bleeding risk carefully |
The Renal RFA Procedure
How percutaneous CT-guided renal RFA is performed in practice.
- 1
Step 1: Pre-Procedure Planning
Review of CT or MRI confirming tumour size, location, and proximity to collecting system, renal vessels, and adjacent structures. eGFR and serum creatinine documented. Nuclear renal split function if single kidney. Biopsy if histology unknown. Anticoagulants held per protocol (typically 5โ7 days for warfarin, 24โ48 hours for newer agents).
- 2
Step 2: Patient Positioning
Patient positioned prone or in lateral decubitus depending on tumour location. Prone position (face down on CT table) for posterior renal tumours โ by far the most common approach. Lateral position for anterolateral tumours. Hydrodissection โ injecting saline between the kidney and adjacent structures โ protects the ureter, bowel, and duodenum from thermal injury.
- 3
Step 3: CT-Guided Electrode Placement
Under intermittent CT guidance, the RFA electrode (typically 17G, 15โ25 cm length) is advanced through the skin and perilesional tissue into the centre of the tumour. Entry angle chosen to maximise the distance between electrode and collecting system. Electrode tip position confirmed in multiple CT planes before energy delivery begins.
- 4
Step 4: Energy Delivery
For tumours <3 cm: single position, 10โ15 minutes ablation. For tumours 3โ4 cm: 2โ3 electrode positions to ensure complete coverage. Temperature at electrode tip 90โ100ยฐC maintained. Internally cooled electrodes prevent charring. Ablation zone extends 0.5โ1 cm beyond tumour margin on all sides.
- 5
Step 5: Immediate Post-Ablation CT
Non-contrast CT immediately after ablation confirms ablation zone size and identifies any immediate complications (perinephric haematoma, pneumothorax if pleural space entered). The ablation zone should encompass the entire original tumour with a visible margin.
- 6
Step 6: Follow-Up Imaging
Contrast-enhanced CT or MRI at 6 weeks confirms complete ablation (no enhancement in treated area). Surveillance CT/MRI every 6 months for 2 years, then annually. eGFR and creatinine at each visit โ to document renal function preservation, which is the key secondary endpoint of renal ablation.
Renal RFA Outcomes Data
Published efficacy, local recurrence, and oncological outcomes from major renal RFA series.
Complete Ablation and Local Recurrence by Size
Technical complete ablation defined as no enhancement on 6-week follow-up imaging.
- Complete Ablation โ RCC <3 cm90โ97%
- Complete Ablation โ RCC 3โ4 cm80โ90%
- 5-Year Local Recurrence-Free Survival (<3 cm)85โ92%
- 5-Year Cancer-Specific Survival โ T1a RCC>95%
Renal Function After RFA vs Partial Nephrectomy
Mean eGFR change at 12 months after RFA vs partial nephrectomy for T1a RCC.
- eGFR Decline โ RFA (12 months)4โ8%
- eGFR Decline โ Partial Nephrectomy (12 months)15โ25%
- eGFR Decline โ Radical Nephrectomy (12 months)45โ55%
RFA vs Partial Nephrectomy: When to Choose Each
The choice between percutaneous RFA and surgical partial nephrectomy for T1a RCC depends on tumour characteristics, patient fitness, and the priority given to function vs oncological precision.
RFA Preferred When...
- Renal Function Preservation Is CriticalSolitary kidney, bilateral tumours, baseline CKD โ every nephron matters.
- High Surgical RiskCardiopulmonary comorbidities, advanced age, prior abdominal surgery increasing anaesthetic risk.
- Small Exophytic TumourPeripheral, exophytic RCC <3 cm โ ideal RFA anatomy; consistent complete ablation.
- Hereditary RCC Requiring Lifetime Multiple TreatmentsVHL, HLRCC, SDH-associated RCC: repeated ablation preserves function across multiple tumour episodes.
- Patient Preference Against SurgeryAfter full counselling on local recurrence trade-off, some patients strongly prefer ablation.
Partial Nephrectomy Preferred When...
- Younger Fit Patient, Normal Contralateral KidneyBest oncological outcome per lesion; pathological staging possible; single definitive treatment.
- Tumour 3โ4 cm (Upper Range)Partial nephrectomy provides better local control for 3โ4 cm tumours where ablation zones are less reliable.
- Hilar or Central LocationCentral hilar location where RFA risks urothelial fistula or vessel injury โ surgery is safer.
- Pathological Staging RequiredSuspected high-grade or sarcomatoid features where histological grade, stage, and margins guide further management.
- Tumour on Anterior Surface Difficult for Percutaneous AccessAnterior tumours with bowel and bowel mesentery in the path โ laparoscopic partial nephrectomy may be safer.
Explore the RFA Knowledge Base
Related RFA topics and resources.
Frequently Asked Questions
Common questions about renal RFA.
About the Procedure
Is the RFA performed through a cut or surgery?
No cuts, no surgery. Percutaneous renal RFA is performed by advancing a needle-thin electrode through the skin directly into the kidney tumour under CT guidance. The entry point is a small needle puncture. No sutures are needed. Patients typically go home the same day or after one overnight stay. The lack of incision is the key practical advantage over laparoscopic or open partial nephrectomy.
My kidney tumour is against the ureter โ can I still have RFA?
A tumour directly adjacent to the renal pelvis or ureter is a technically challenging location for RFA, because the heat generated can damage the collecting system and cause a urothelial fistula or stricture. At highly experienced centres, this can sometimes be managed with pyeloperfusion (chilled saline instilled into the collecting system to protect it during ablation). For most patients with central hilar tumours, partial nephrectomy โ which allows the surgeon to directly visualise and protect the collecting system โ is the safer approach. CancerFax can assess your specific CT to advise on suitability.
About Outcomes
What if my RFA is incomplete โ will I need surgery?
Incomplete ablation (residual enhancement at 6-week follow-up) occurs in approximately 5โ15% of cases, more often for larger tumours near vessels. The standard response is repeat percutaneous RFA โ achieving complete ablation in the majority of re-treated cases. Surgery (partial nephrectomy) is reserved for cases where repeat ablation fails or is not technically feasible. Prior RFA does not preclude subsequent partial nephrectomy.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Small Kidney Tumour? Preserve Your Kidney with Percutaneous RFA.
Upload your kidney CT/MRI, eGFR, and biopsy results if available. Our urologic oncology team will assess whether percutaneous RFA is the right approach to protect your kidney function.
For informational purposes only. Renal mass treatment decisions require evaluation by qualified urologic oncology and interventional radiology specialists.